211 related articles for article (PubMed ID: 31604903)
21. Coactivated platelet-derived growth factor receptor {alpha} and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma.
Dewaele B; Floris G; Finalet-Ferreiro J; Fletcher CD; Coindre JM; Guillou L; Hogendoorn PC; Wozniak A; Vanspauwen V; Schöffski P; Marynen P; Vandenberghe P; Sciot R; Debiec-Rychter M
Cancer Res; 2010 Sep; 70(18):7304-14. PubMed ID: 20685895
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive Genomic Profiling of Adult Renal Sarcomas Provides Insight into Disease Biology and Opportunities for Targeted Therapies.
Yakirevich E; Madison R; Fridman E; Mangray S; Carneiro BA; Lu S; Cooke M; Bratslavsky G; Webster J; Ross JS; Ali SM
Eur Urol Oncol; 2021 Apr; 4(2):282-288. PubMed ID: 31412008
[TBL] [Abstract][Full Text] [Related]
23. Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas.
Martinho O; Longatto-Filho A; Lambros MB; Martins A; Pinheiro C; Silva A; Pardal F; Amorim J; Mackay A; Milanezi F; Tamber N; Fenwick K; Ashworth A; Reis-Filho JS; Lopes JM; Reis RM
Br J Cancer; 2009 Sep; 101(6):973-82. PubMed ID: 19707201
[TBL] [Abstract][Full Text] [Related]
24. Silent mutations in KIT and PDGFRA and coexpression of receptors with SCF and PDGFA in Merkel cell carcinoma: implications for tyrosine kinase-based tumorigenesis.
Kartha RV; Sundram UN
Mod Pathol; 2008 Feb; 21(2):96-104. PubMed ID: 18084259
[TBL] [Abstract][Full Text] [Related]
25. Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors.
McDermott U; Ames RY; Iafrate AJ; Maheswaran S; Stubbs H; Greninger P; McCutcheon K; Milano R; Tam A; Lee DY; Lucien L; Brannigan BW; Ulkus LE; Ma XJ; Erlander MG; Haber DA; Sharma SV; Settleman J
Cancer Res; 2009 May; 69(9):3937-46. PubMed ID: 19366796
[TBL] [Abstract][Full Text] [Related]
26. The three receptor tyrosine kinases c-KIT, VEGFR2 and PDGFRα, closely spaced at 4q12, show increased protein expression in triple-negative breast cancer.
Jansson S; Bendahl PO; Grabau DA; Falck AK; Fernö M; Aaltonen K; Rydén L
PLoS One; 2014; 9(7):e102176. PubMed ID: 25025175
[TBL] [Abstract][Full Text] [Related]
27.
Klempner SJ; Madison R; Pujara V; Ross JS; Miller VA; Ali SM; Schrock AB; Kim ST; Maron SB; Dayyani F; Catenacci DVT; Lee J; Chao J
Oncologist; 2019 Nov; 24(11):1462-1468. PubMed ID: 31249137
[TBL] [Abstract][Full Text] [Related]
28. Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma.
Longatto-Filho A; Pinheiro C; Martinho O; Moreira MA; Ribeiro LF; Queiroz GS; Schmitt FC; Baltazar F; Reis RM
BMC Cancer; 2009 Jun; 9():212. PubMed ID: 19563658
[TBL] [Abstract][Full Text] [Related]
29. A YAC contig spanning a cluster of human type III receptor protein tyrosine kinase genes (PDGFRA-KIT-KDR) in chromosome segment 4q12.
Spritz RA; Strunk KM; Lee ST; Lu-Kuo JM; Ward DC; Le Paslier D; Altherr MR; Dorman TE; Moir DT
Genomics; 1994 Jul; 22(2):431-6. PubMed ID: 7528718
[TBL] [Abstract][Full Text] [Related]
30. Recurrent CIC Gene Abnormalities in Angiosarcomas: A Molecular Study of 120 Cases With Concurrent Investigation of PLCG1, KDR, MYC, and FLT4 Gene Alterations.
Huang SC; Zhang L; Sung YS; Chen CL; Kao YC; Agaram NP; Singer S; Tap WD; D'Angelo S; Antonescu CR
Am J Surg Pathol; 2016 May; 40(5):645-55. PubMed ID: 26735859
[TBL] [Abstract][Full Text] [Related]
31. Fluorescent In Situ Hybridization Must be Preferred to pan-TRK Immunohistochemistry to Diagnose NTRK3-rearranged Gastrointestinal Stromal Tumors (GIST).
Castillon M; Kammerer-Jacquet SF; Cariou M; Costa S; Conq G; Samaison L; Douet-Guilbert N; Marcorelles P; Doucet L; Uguen A
Appl Immunohistochem Mol Morphol; 2021 Sep; 29(8):626-634. PubMed ID: 33758144
[TBL] [Abstract][Full Text] [Related]
32. High KIT and PDGFRA are associated with shorter patients survival in gastroenteropancreatic neuroendocrine tumors, but mutations are a rare event.
Knösel T; Chen Y; Altendorf-Hofmann A; Danielczok C; Freesmeyer M; Settmacher U; Wurst C; Schulz S; Yang LL; Petersen I
J Cancer Res Clin Oncol; 2012 Mar; 138(3):397-403. PubMed ID: 22160160
[TBL] [Abstract][Full Text] [Related]
33. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response.
Szerlip NJ; Pedraza A; Chakravarty D; Azim M; McGuire J; Fang Y; Ozawa T; Holland EC; Huse JT; Jhanwar S; Leversha MA; Mikkelsen T; Brennan CW
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3041-6. PubMed ID: 22323597
[TBL] [Abstract][Full Text] [Related]
34. Positive immunohistochemical staining of KIT in solid-pseudopapillary neoplasms of the pancreas is not associated with KIT/PDGFRA mutations.
Cao D; Antonescu C; Wong G; Winter J; Maitra A; Adsay NV; Klimstra DS; Hruban RH
Mod Pathol; 2006 Sep; 19(9):1157-63. PubMed ID: 16778826
[TBL] [Abstract][Full Text] [Related]
35. EGFR and PDGFRA co-expression and heterodimerization in glioblastoma tumor sphere lines.
Chakravarty D; Pedraza AM; Cotari J; Liu AH; Punko D; Kokroo A; Huse JT; Altan-Bonnet G; Brennan CW
Sci Rep; 2017 Aug; 7(1):9043. PubMed ID: 28831081
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
[TBL] [Abstract][Full Text] [Related]
37. PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas.
Ozawa T; Brennan CW; Wang L; Squatrito M; Sasayama T; Nakada M; Huse JT; Pedraza A; Utsuki S; Yasui Y; Tandon A; Fomchenko EI; Oka H; Levine RL; Fujii K; Ladanyi M; Holland EC
Genes Dev; 2010 Oct; 24(19):2205-18. PubMed ID: 20889717
[TBL] [Abstract][Full Text] [Related]
38. Array comparative genomic hybridization reveals frequent alterations of G1/S checkpoint genes in undifferentiated pleomorphic sarcoma of bone.
Niini T; Lahti L; Michelacci F; Ninomiya S; Hattinger CM; Guled M; Böhling T; Picci P; Serra M; Knuutila S
Genes Chromosomes Cancer; 2011 May; 50(5):291-306. PubMed ID: 21254299
[TBL] [Abstract][Full Text] [Related]
39. Expression of platelet-derived growth factor-alpha receptor and c-kit in giant cell tumours of bone.
Sulzbacher I; Dominkus M; Pichlhofer B; Mazal PR
Pathology; 2009; 41(7):630-3. PubMed ID: 20001342
[TBL] [Abstract][Full Text] [Related]
40. Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma.
Lassus H; Sihto H; Leminen A; Nordling S; Joensuu H; Nupponen NN; Butzow R
Br J Cancer; 2004 Dec; 91(12):2048-55. PubMed ID: 15583695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]